Gastroenteropancreatic Neuroendocrine Tumor Clinical Trials

8 recruiting

Frequently Asked Questions

Common questions about Gastroenteropancreatic Neuroendocrine Tumor clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 111 of 11 trials

Recruiting
Phase 3

Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET

Somatostatin Receptor Positive (SSTR+)Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Novartis Pharmaceuticals240 enrolled62 locationsNCT06784752
Recruiting
Phase 3

Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

Neuroendocrine TumorsGep NetCarcinoid Tumor+4 more
RayzeBio, Inc.288 enrolled54 locationsNCT05477576
Recruiting

Nutritional Status Assessment in Adult Patients Followed for Gastroenteropancreatic Neuroendocrine Tumors at Strasbourg University Hospital

Gastroenteropancreatic Neuroendocrine Tumor
University Hospital, Strasbourg, France100 enrolled1 locationNCT07302100
Recruiting
Phase 1Phase 2

Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Neuroendocrine Tumors

ParagangliomaPheochromocytomaNeuroendocrine Tumors Unresectable+3 more
Perspective Therapeutics260 enrolled17 locationsNCT05636618
Recruiting
Phase 2

IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers

Peritoneal MesotheliomaAnaplastic Thyroid CarcinomasCarcinoid Tumor+3 more
Hospices Civils de Lyon154 enrolled15 locationsNCT06790706
Recruiting
Not Applicable

Multi-modal Characterisation of Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) Treated With Targeted Radionuclide Therapy (TRT): Prospective Interventional Multicentre National Cohort

RadiotherapyGastroenteropancreatic Neuroendocrine Tumor
Assistance Publique - Hôpitaux de Paris80 enrolled5 locationsNCT06256705
Recruiting
Phase 1

Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery

Gastroenteropancreatic Neuroendocrine Tumor
Stanford University10 enrolled1 locationNCT04609592
Recruiting
Phase 3

Gallium (68Ga) Edotreotide PET/CT for Imaging Patients With Gastrointestinal Pancreatic Neuroendocrine Tumors

Advanced Gastroenteropancreatic Neuroendocrine Tumor
Jiangsu HengRui Medicine Co., Ltd.66 enrolled1 locationNCT06091748
Recruiting
Phase 4

Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients

Gastroenteropancreatic Neuroendocrine Tumor
University Hospital, Antwerp270 enrolled19 locationsNCT05701241
Recruiting

68Ga-DOTATOC PET for the Evaluation of Gastroenteropancreatic Neuroendocrine Tumours

Gastroenteropancreatic Neuroendocrine Tumor
IRCCS San Raffaele300 enrolled1 locationNCT06155318
Recruiting
Phase 3

An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.

Advanced Gastroenteropancreatic Neuroendocrine Tumor
Jiangsu HengRui Medicine Co., Ltd.220 enrolled1 locationNCT05884255